Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022

$3,495.00

The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2022
Number of pages
450+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP22061

The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022 report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.  The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. 

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2015, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2015. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2015. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2015. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

 

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.

Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials includes:

 

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 700 infectious vaccines deal records
  • Identify the most active infectious vaccine dealmakers since 2015
  • The leading infectious vaccines deals by value since 2015
  • Includes adjuvant deals and alliances since 2015

  

In Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific infectious therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 700 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of infectious vaccines deal trends since 2015
  • Access infectious vaccines deal headline, upfront, milestone and royalty data
  • Comprehensive access to over 700 links to actual infectious vaccines deals entered into by the world’s biopharma companies, together with real world clause examples
  • Identify leading infectious vaccines deals by value since 2015
  • Identify the most active infectious vaccines dealmakers since 2015
  • Insight into the terms included in infectious vaccines agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Infectious Vaccines dealmaking

 

2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

 

Chapter 3 – Leading Infectious Vaccines deals

 

3.1. Introduction
3.2. Top Infectious Vaccines deals by value

 

Chapter 4 – Most active Infectious Vaccines dealmakers

 

4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles

 

Chapter 5 – Infectious Vaccines contracts dealmaking directory

 

5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory

 

Chapter 6 – Infectious Vaccines dealmaking by technology type

 

Appendices

Appendix 1 – Infectious Vaccines deals by company A-Z

Appendix 2 – Infectious Vaccines deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 – Infectious Vaccines deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

Appendix 4 – Infectious Vaccines deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading on dealmaking

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Infectious Vaccines partnering since 2015
Figure 2: Active Infectious Vaccines dealmaking activity since 2015
Figure 3: Infectious Vaccines partnering by deal type since 2015
Figure 4: Infectious Vaccines partnering by disease type since 2015
Figure 5: Infectious Vaccines deals with a headline value
Figure 6: Infectious Vaccines deals with an upfront value
Figure 7: Infectious Vaccines deals with a milestone value
Figure 8: Infectious Vaccines deals with a royalty rate value
Figure 9: Top Infectious Vaccines deals by value since 2015
Figure 10: Most active Infectious Vaccines dealmakers since 2015

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2A, A*STAR’ Institute of Molecular and Cell Biology, ABEC, ABL Bio, Abnova, Abogen Biosciences, Academy of Military Medical Sciences (China), Adaptive Phage Therapeutics, AdaptVac, Adjuvance Technologies, Aduro BioTech, Advaccine Biotechnology, Advanced Biological Laboratories, Advanced BioNutrition, Advent International, Aegis Life, Aelix Therapeutics, Aeras, Aerogen, Affinivax, AGC Biologics, Agenus Bio, AIM ImmunoTech, Akers Biosciences, Akshaya Bio, Akston Biosciences, Albany Molecular Research, Alberta Cell Therapy Manufacturing, Alcami, Aldevron, Algenex, Altimmune, American Gene Technologies, AmerisourceBergen, Amyris, AnGes MG, Antitope, Appili Therapeutics, Applied DNA Sciences, Aptimmune Biologics, Aragen Bioscience, Arcturus Therapeutics, Ardigen, Aridis Pharmaceuticals, Artes Biotechnology, Asopharma, Astellas Pharma, AstraZeneca, AuraVax Therapeutics, Aurobindo Pharma, Avanzcare, Avid Bioservices, Avidea Technologies, Batavia Biosciences, Battelle, Bavarian Nordic, Baxter International, Baylor College, Baylor College of Medicine, Baylor Institute for Immunology Research, Beth Israel Deaconess Medical Center, Bharat Biotech, BIA Separations, Bill and Melinda Gates Foundation, Binex, Bintai Kinden, BioComo, bioCSL, Biodextris, Biofabri, Biofactura, Bio Farma, BioIQ, Biolexis, BioLife Solutions, Biological E, Biomedical Advanced Research and Development Authority, BiondVax, BioNet Holding, BioNTech, BioSun Pharmed, Biotechnology Industry Research Assistance Council, Biovac, BioVaxys, Blanver, Blue Water Vaccines, BlueWillow Biologics, Boehringer Ingelheim, BravoVax, Brickell Biotech, Brighton Biotech, BTG, Burnet Institute, Butantan Institute, CanSinoBIO, CARB-X, CaroGen, Catalent, Catholic University Leuven, CCT Research, Celdara Medical, Celonic, Celsion, Centers for Disease Control and Prevention, Changchun BCHT Biotechnology, Children's Hospital Boston, Chimeron Bio, China National Biotech Group (CNBG), Cilian, CimCure, Cincinnati Children’s Hospital Medical Center, CIRION BioPharma Research, Citranvi Biosciences, City College of New York, City of Hope, Clarametyx Biosciences, ClearPath, Clover Biopharmaceuticals, CMC Biologics, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Codagenix, Codiak BioSciences, Colombia Ministry of Health and Social Protection, ConserV Bioscience, Corden Pharma, COVAX, COVAXX, Cristal Therapeutics, Crozet BioPharma, Crucell, CryoPort, CSIRO, CSL, Curative Biotechnology, CureVac, CVC, CyanVac, Cystron Biotech, Cytiva, Cytovance Biologics, Dalton Pharma Services, Debiopharm, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Delpharm, Department of Defence, Department of Defense, Department of Health and Human Services, Diavax Biosciences, Dow Chemical, Dr. Reddy's Laboratories, Duke-NUS Graduate Medical School Singapore, Duke University, Dyadic International, Dynavax Technologies, DynPort Vaccine Company, Eddingpharm, Eli Lilly, Elixirgen, Emergent BioSolutions, Emergex Vaccines, Emmes, Emory University, Emulate, Endo International, Enesi Pharma, Engility, Ennaid Therapeutics, Entos Pharmaceuticals, Enzychem Lifesciences, Epivax, EpiVax Therapeutics, Epygen Biotech, eTheRNA immunotherapies, Etna Biotech, Eurocine Vaccines, Eurofarma, European Commission, European Union, Evaxion Biotech, Everest Medicines, EVQLV, Excivion, Exothera, ExpreS2ion Biotechnologies, Eyam Vaccines and Immunotherapeutics, Eyegene, Fareva Holding, Farmacore Biotechnology, Fatro, Federal Ministry of Education and Research (BMBF), Fina Biosolutions, Flow Pharma, FluGen, Food and Drug Administration (FDA), Fortress Biotech, Fosun Pharmaceutical, Foundation for Biomedical Research and Innovation, Frazier Healthcare Ventures, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Fujifilm Diosynth Biotechnologies, Gamaleya National Center, GAVI Alliance, GC Pharma, GE Healthcare, GeneOne Life Science, Generex Biotechnology, Genetic Immunity, Geneva Foundation, Genevant Sciences, Genexine, Genkyotex, Gennova Biopharmaceuticals, Genocea Biosciences, Genomma Lab Internacional, GenScript ProBio, Genticel, GenVec, George Mason University, Georgia State University Research Foundation (GSURF), Georgia Tech Research Corporation, GeoVax, German Cancer Research Center, German Federal Ministry of Education and Research, German Government, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glide Technologies, Global Health Innovative Technology Fund (GHIT), Global Virus Network, Global WholeHealth Partners, Government of Argentina, Government of Australia, Government of Bahrain, Government of Canada, Government of France, Government of Germany, Government of India, Government of Israel, Government of Japan, Government of Netherlands, Government of Serbia, Government of South Korea, Government of Switzerland, Government of The Philippines, Grameen Health, Grand River Aseptic Manufacturing, Greenlight Biosciences, Greenwich LifeSciences, Gritstone Bio, GTP Bioways, Guangzhou Institute of Respiratory Disease, Halix, HaloVax, HanaVax, Harro Hofliger, Harvard Medical School, Harvard University, Hawaii Biotech, HDT Bio, Healthcare Royalty Partners, Health Decisions, Heat Biologics, Henry M. Jackson Foundation, HilleVax, Horizon 2022, Hoth Therapeutics, Howard Hughes Medical Institute (HHMI), Hualan Biological Bacterin, Human Vaccines Project, hVIVO, Iaso Therapeutics, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, Iconovo, IDT Biologika, ImmBio, Immorna, Immune System Regulation, ImmunityBio, Immunomic, ImmunoPrecise Antibodies, ImmunoScape, Immunovaccine, Immuron, Imperial College London, Imutex, Indian Council of Medical Research, Infectious Disease Research Institute (IDRI), Infor, InnoCentive, Innovate UK, Innovative Medicines Initiative (IMI), Innovo, Inovio, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Institute for Bioscience and Biotechnology Research, Institut Pasteur, Integral Molecular, Integrated BioTherapeutics, International AIDS Vaccine Initiative, International Vaccine Institute (IVI), Intravacc, Inventprise, Ippox Foundation, IQVIA, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Israel Investment Center, Italian Government, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Government, Jenner Institute, Johnson & Johnson, JSC Pharmadis, Jubilant Hollisterstier, Junshi Biosciences, Kaneka, Kansas State University, Karolinska Institute, KBI BioPharma, Kemin Industries, Kermode Biotechnologies, Kindred Bio, King Saud University, Kiromic Biopharma, Kleo Pharmaceuticals, Korea Advanced Institute of Science and Technology, Laboratorios Farmaceuticos Rovi, Laboratory of Malaria Immunology and Vaccinology (LMIV), La Jolla Institute for Allergy & Immunology, LakePharma, Last Chance for Children, Lawrence Livermore National Laboratory, Laxisam, Leiden University, Leidos, Leukocare, LinKinVax, LiteVax, Longeveron, Lonza, Lumos Pharma, Lund University, Macquarie University, Maersk-Andersen, Magenta Investments, Maryland Technology Development Corporation, Massachusetts General Hospital, Massachusetts Life Sciences Center, Matrivax, McKesson, McMaster University, Medicago, Medical University of Vienna, MediciNova, MediGene, Medigen Vaccine Biologics, MedImmune, Medison Pharma, Medlab Clinical, Medytox, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Metaclipse Therapeutics, Mexican National Technology and Science Council, Micron Biomedical, Mid-Atlantic BioTherapeutics, Midatech, Mie University, MilliporeSigma, Minapharm, MinervaX, Ministry of Health, Ministry of Health (Denmark), Ministry of Health (Israel), Ministry of Health, Labor and Welfare, MLU Services, MMS, Moderna Therapeutics, Molipharma, MphRx, MSD Wellcome Trust Hilleman Laboratories, Mucosis, Mundo Sano, Mymetics, Myriad RBM, Mytide Therapeutics, NanoBio, NanoPass Technologies, Nant Africa, NantKwest, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Cholera and Enteric Diseases, National Institute of Hygiene and Epidemiology, National Institute of Infectious Diseases, National Institute of Vaccines and Medical Biologicals, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, National Research Council Canada, National Research Council Industrial Research Assistance Program, National Research Council of Canada, National Science Foundation, Natural Sciences and Engineering Research Council of Canada, Nature Technology, Naval Medical Research Center, Navigo Proteins, New Zealand's Foundation for Research, Science and Technology, Nexelis, Noachis Terra, Nobelpharma, Northern RNA, Novartis, Novavax, Novo, NRx Pharmaceuticals, Nuance Pharma, NuGenerex Immuno-Oncology, Nunzia Pharmaceutical, Nykode Therapeutics, Oberland Capital, Ocugen, Ohio State University, Ology Bioservices, Open Orphan, Oragenics, Oramed Pharmaceuticals, Oravax Medical, OSE Immunotherapeutics, Osivax, Oswaldo Cruz Foundation (Fiocruz), Ottawa Hospital Research Institute, Owkin, Oxgene, Pacific GeneTech, Panacea Biotech, Partnership for Influenza Vaccine Introduction, PATH (Appropriate Technology in Health), PATH Malaria Vaccine Initiative, PaxVax, PDS Biotechnology, PepTcell, Perelman School of Medicine, Pfenex, Pfizer, Pharco Pharma, Pharm-Olam International, PharmaJet, Pharma Science, PharmAthene, PHC, PlantForm, PnuVax, Pohang University Of Science And Technology, PolyPeptide Group, Poly Pharmaceuticals, POSCO International, PPD, Precision NanoSystems, Precision Virologics, Premas Biotech, Prestige BioPharma, ProBioGen, Probiomed, Profectus Biosciences, Prokarium, Protein Sciences, Providence Therapeutics, PT Bio Farma, Public Health Agency of Canada, Public Health England, Public Health Vaccines, Quebec Government, Quratis, R-Pharm, Ragon Institute, Rapid Dose Therapeutics, Rapid Micro Biosystems, Recipharm, Refana, Regeneron Pharmaceuticals, ReiThera, Rentschler Biotechnologie, Repligen, Reyon Pharmaceuticals, Rockefeller University, RocketVax, Rokote Laboratories, Russian Direct Investment Fund, Sabin Vaccine Institute, Saiba, Samsung Biologics, Sanaria, Sanofi, Sanofi-Pasteur, Sartorius, Scancell, Scandinavian Biopharma, Science 37, SciSafe, Scottish Enterprise, Scripps Research Institute, SEEK, Selexis, Sementis, Senai Cimatec, Seoul National University, Seppic, Serum Institute of India, Shenzhen Kangtai Biological Products, Shionogi, Shionogi Pharma, Sinergium Biotech, Sinopharm Group Beijing HuaHong, Sinotek-Advocates International Industry Development, Sinovac Biotech, SiO2 Medical Products, SK Bioscience, Small Business Innovation Research, SmartPharm Therapeutics, Smiths Medical, Soligenix, Sorrento Therapeutics, Southern Research Institute, Spicona, SRI International, St. Jude Children's Research Hospital, Stanford University, Stelis Biopharma, Stellar Biotechnologies, Strategic Vaccines, Sudpack Medica, Sunstone Capital, SutroVax, Symbiosis, Symvivo, Synairgen, Syngene International, Tabuk Pharmaceutical, Taiwan Ministry of Economic Affairs, Takara Bio, Takeda Pharmaceutical, Takis Biotech, Talem Therapeutics, Technical University of Denmark (DTU), TechnoVax, Texas A&M University, Texas Biomedical Research Institute, Texas Children’s Hospital, TFF Pharmaceuticals, The International AIDS Vaccine Initiative, The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center, Themis Bioscience, The Native Antigen Company, Therapure Biopharma, Therapyx, Thermo Fisher Scientific, Thomas Jefferson University, Tianjin CanSino Biotechnology, Tobin Scientific, TONIX Pharmaceuticals, Trans-Hit Bio, Translate Bio, Transtoxbio, Trianni, TriLink BioTechnologies, Trinity Pharmaceuticals, UK Government, UMN Pharma, United Nations Children Fund, Univercells, University of Adelaide, University of Alabama at Birmingham, University of Alberta, University of British Columbia, University of California, Davis, University of California Berkeley, University of Chicago, University of Copenhagen, University of Edinburgh, University of Georgia, University of Guelph, University of Hawaii, University of Helsinki, University of Houston, University of Maryland, University of Maryland School of Medicine, University of Massachusetts, University of Miami, University of Miami Miller School of Medicine, University of Montreal, University of Nagasaki, University of Nebraska, University of New South Wales, University of Oxford, University of Pennsylvania, University of Queensland, University of Saskatchewan, University of Southampton, University of Tennessee, University of Texas, University of the Witwatersrand, University of Tokyo, University of Tubingen, University of Wisconsin-Madison, US Army, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, US Biologic, US Department of Agriculture, US Government, Utrecht University, Vaccitech, Valera Pharmaceutical, Valneva, Valo Therapeutics, Variation Biotechnologies, VaxAlta, Vaxart, Vaxeal, Vaxess Technologies, Vaxil BioTherapeutics, Vaxine, VaxNewMo, VaxThera, Vaxxas, VBI Vaccines, Veristat, Verndari, Versatope Therapeutics, Vibalogics, Vical, Vigene Biosciences, Vinbiocare Biotechnology, Viravaxx, Vir Biotechnology, Virchow Biotech, ViveBio, VLP Therapeutics, Voltron Therapeutics, Wacker Chemie, Wageningen University, Walter Reed Army Institute of Research, Washington University in St Louis, WCCT Global, Wellcome Trust, Westport Bio, Wipro, Wistar Institute, WuXi Biologics, Xenetic Biosciences, Yale University, Yisheng Biopharma, Yunnan Walvax Biotech, ZandCell, Zolovax, Zuellig Pharma China, Zydus Cadila, ZYUS Life Sciences

urrent Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!